Fig. 2.

Proportion of PWH in switch cohorts treated with DTG + 3TC reporting effectiveness at Week 48. Data included for studies with N ≥ 100. Duplicate studies have been removed. DTG dolutegravir, PP per protocol, PWH people with HIV, PYFU person-years of follow-up, 3TC lamivudine, VF virologic failure, VL viral load, VR virologic rebound. ^aN = 772 PWH with no prior VF; N = 194 PWH with ≥ 1 prior VF. ^bN is for overall population and includes 6 PWH who were not suppressed at baseline